Prothena (PRTA) Expected to Announce Earnings on Thursday

Prothena (NASDAQ:PRTA) is expected to be announcing its earnings results after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of ($1.02) per share and revenue of $7.53 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Prothena Trading Up 2.0 %

NASDAQ PRTA opened at $14.17 on Tuesday. The company has a market capitalization of $762.49 million, a PE ratio of -5.71 and a beta of 0.08. Prothena has a 1-year low of $11.70 and a 1-year high of $31.03. The firm’s fifty day simple moving average is $14.24 and its 200-day simple moving average is $16.90.

Analysts Set New Price Targets

A number of analysts recently weighed in on PRTA shares. HC Wainwright reissued a “buy” rating and issued a $48.00 price target (down previously from $84.00) on shares of Prothena in a report on Friday, December 20th. Oppenheimer upped their target price on shares of Prothena from $58.00 to $62.00 and gave the company an “outperform” rating in a report on Friday, February 7th. Bank of America decreased their target price on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a research report on Thursday, December 19th. Chardan Capital began coverage on shares of Prothena in a research note on Friday, December 20th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, StockNews.com downgraded shares of Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.